Routine vaccines across the life span, 2005

Journal of Family Practice

Volumn 54, Issue SUPPL. 1, 2005, Pages

  Zimmerman, Richard Kent ^a,b   Middleton, Donald B ^a   Burns, Ilene Timko ^a,c   Clover, Richard D ^d   Kimmel, Sanford R ^e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c School of Medicine ^*  (United States)

^d University of Louisville School of Medicine   (United States)

^e MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PEDIARIX; PERTUSSIS VACCINE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; TRIHIBIT; VACCINE;

ALLERGIC REACTION; ANAPHYLAXIS; ARTHRALGIA; ARTHRITIS; AUTISM; BACTEREMIA; BRACHIAL PLEXUS NEUROPATHY; BRAIN DISEASE; BRAIN INJURY; CHICKENPOX; CLINICAL TRIAL; CRYING; DIPHTHERIA; DRUG EFFICACY; EDEMA; ERYTHEMA; FATIGUE; FEVER; HEADACHE; HEART FAILURE; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INJECTION PAIN; LIFESPAN; LYMPHADENOPATHY; MALAISE; MEASLES; MENINGITIS; MENINGOCOCCOSIS; MUMPS; MYOCARDITIS; NEISSERIA MENINGITIDIS; NERVOUS SYSTEM INJURY; NEURITIS; OPISTHOTONUS; ORCHITIS; PERTUSSIS; PNEUMONIA; POLIOMYELITIS; RASH; REVIEW; RUBELLA; SEIZURE; SIDE EFFECT; SUBACUTE SCLEROSING PANENCEPHALITIS; TETANUS; THROMBOCYTOPENIA; TRISMUS;

AGE FACTORS; CHICKENPOX VACCINE; HEPATITIS A VACCINES; HEPATITIS B VACCINES; HUMANS; INFLUENZA VACCINES; MEASLES-MUMPS-RUBELLA VACCINE; MENINGOCOCCAL VACCINES; PERTUSSIS VACCINE; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINES; VIRAL VACCINES;

EID: 12144251146     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Centers for Disease Control and Prevention. Summary of notifiable diseases - United States, 2002. MMWR Morb Mortal Wkly Rep. 2004;51:1-84
2. Moyer LA, Mast EE. Hepatitis B: virology, epidemiology, disease, and prevention, and an overview of viral hepatitis. Am J Prev Med. 1994;10(suppl):45-55.
3. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA. 1990;203:1218-1222.
4. Petersen NJ, Barrett DH, Bond WW, et al. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Appl Environ Microbiol. 1976;32:572-574.
5. Franks AL, Berg CJ, Kane MA, et al. Hepatitis B virus infection among children born in the United States to Southeast Asian refugees [published correction appears in N Engl J Med. 1990;322:280] [see comments]. N Engl J Med. 1989;321:1301-1305.
6. Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics. 1992;89:269-273.
7. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA. 1995;274:1201-1208.
8. Saari TN. Immunization of preterm and low birth weight infants. Pediatrics. 2003;112:193-198.
9. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001;344:327-332.
10. West DJ, Margolis HS. Prevention of hepatitis B virus infection in the United States: a pediatric perspective. Pediatr Infect Dis J. 1992;11:866-874.
11. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 8th ed. Washington, DC: Public Health Foundation; 2004.
12. Centers for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. MMWR Recomm Rep. 1997;46:1-25.
13. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 1995;96(suppl): 557-566.
14. Institute of Medicine. Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. Howson CP, Howe CJ, Fineberg HV. Adverse Effects of Pertussis and Rubella Vaccines: A Report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. Washington, DC: National Academy Press; 1991.
15. Centers for Disease Control and Prevention. Update: vaccine side effects, adverse reactions, contraindications, and precautions - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996;45:1-35.
16. Nelson JD, The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. Am J Dis Child. 1978;132:371-373.
17. American College of Physicians Task Force on Adult Immunization, Infectious Diseases Society of America. Guide for Adult Immunization. Philadelphia, Pa: American College of Physicians; 1994.
18. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46:1-24.
19. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1-38.
20. Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics. 1999;103:E28.
21. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med. 2000;342:681-689.
22. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM 197 in United States infants. Pediatrics. 1998;101:604-611.
23. Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 1999;18:757-763.
24. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-195.
25. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
26. Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283:1460-1468.
27. Pickering LD. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, Ill: American Academy of Pediatrics; 2003.
28. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine: recommendations of the Advisory Committee on Immunization Practices (AC1P). MMWR Recomm Rep. 1997;46:1-25.
29. Thoms ML, Bodnar PZ, O'Donovan JC, Gouel EG, Walcher JR, Halsey NA, Parental knowledge and choice regarding live and inactivated poliovirus vaccines. Arch Pediatr Adolesc Med. 1997;151:809-812.
30. Centers for Disease Control and Prevention. Vaccines and Autism Theory. Atlanta, Ga: Centers for Disease Control and Prevention; 2004. Available at: www.cdc.gov/nip/vacsafe/concerns/autism/default.htm.
31. Primer on the Rheumatic Diseases. 12th ed. Atlanta, Ga: Arthritis Foundation; 2001.
32. Stratton KR, Howe CJ, Johnston RB, Jr. Adverse Events Associated With Childhood Vaccines: Evidence Bearing on Causality. Washington. DC: National Academy Press; 1994.
33. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287:606-611.
34. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for U.S. children. JAMA. 1994;271:375-381.
35. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996;45:1-25.
36. Vazquez M, LaRussa PS, Gershon AA, Steinberg SPO, Freudigman K, Shapiro ED. The effectiveness of varicella vaccine in clinical practice. N Engl J Med. 2001;344:955-960.
37. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002;347:1909-1915.
38. Fine PEM, Zell ER. Outbreaks in highly vaccinated populations: implications for studies of vaccine performance. Am J Epidemiol. 1994;139:77-90.
39. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella vaccinated cases: a household contact study. JAMA. 2004;292:704-708.
40. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol. 1994;140:81-104.
41. Asano Y, Suga S, Yoshikawa T, et al. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics. 1994;94:524-526.
42. Johnson CE, Stancin T, Fattlar D, Rome LP, Kumar ML. A long-term prospective study of varicella vaccine in healthy children. Pediatrics. 1997;100:761-766.
43. Centers for Disease Control and Prevention. Outbreak of varicella among vaccinated children - Michigan. 2003. MMWR Morb Mortal Wkly Rep. 2004;53:389-392.
44. Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J. 1998;17:256-257.
45. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics. 1986;78:748-756.
46. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999;48:1-37.
47. McCaustland KA, Bond WW, Bradley DW, Ebert JW, Maynard JE. Survival of hepatitis A virus in feces after drying and storage for 1 month. J Clin Microbiol. 1982;16:957-958.
48. Bell BP, Shapiro CS, Alter MJ, et al. The diverse patterns of hepatitis A epidemiology in the United States - implications for vaccination strategies. J Infect Dis. 1998;178:1579-1584.
49. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis. 1995;171:S44-S49.
50. Werzberger A, Mensch B, Taddeo C, et al. 6-year follow-up of children and adolescents who participated in an efficacy trial of VAQTA (hepatitis A vaccine, inactivated, Merck). Conference Abstracts of the 32nd National Immunization Conference. 1998. Abstract 078.
51. Wiedermann G, Kindi M, Ambrosch F. Estimated persistence of anti-HAV antibodies after a single dose and booster hepatitis A vaccination (0-6 schedule). Acta Trop. 1998;69:121-125.
52. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2000;49:1-10.
53. Offit PA, Peter G. The meningococcal vaccine: public policy and individual choices. N Engl J Med. 2003;349:2353-2356.
54. Apicella MA. Neisseria meningitidis. In: Mandell GL, Bennet JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, Pa: Churchill-Livingstone; 2000:2228-2241.
55. Harrison LH, Dwyer DM, Maples CT, Billmann L. Risk of meningococcal infection in college students. JAMA. 1999;281:1906-1910.
56. Harrison LH, Pass MA, Mendelsohn AB, et al. Invasive meningococcal disease in adolescents and young adults. JAMA. 2001;286:694-699.
57. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA. 2001;286:688-693.
58. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ. 2000;320:846-849.
59. Ramsay ME, Andrews N, Kaczmarski EB, Milier E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 2001;357:195-196.
60. Campbell JD, Edelman R, King JC Jr, Papa T, Ryall R, Rennels MB. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis. 2002;186:1848-1851.
61. Overturf GD, Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis (RE9960). Pediatrics. 2000;106:367-376.
62. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747-1755.
63. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med. 1994;154:2666-2677.
64. Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 Western European countries. Clin Infect Dis. 2000;31:444-450.
65. Jackson LA, Benson P, Sneller VP. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA. 1999;281:243-244.
66. Fedson DS, Harward MP, Reid RA, Kaiser DL. Hospital-based pneumococcal immunization. Epidemiologic rationale front the Shenandoah study. JAMA. 1990;264:1117-1122.